Results 101 to 110 of about 2,379 (179)

Elexacaftor-tezacaftor-ivacaftor enhances first-phase insulin secretion and improves glucose control in cystic fibrosis. [PDF]

Endocr Connect
Edlund A, Lindberg U, Fagher K, Påhlman LI.   +3 more
europepmc   +1 more source

Real-World Outcomes of Elexacaftor/Tezacaftor/Ivacaftor in Children with Cystic Fibrosis. [PDF]

Ann Am Thorac Soc
Perrem L, McNally P.
europepmc   +1 more source

Real-World Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis: A 24-Month Italian National Registry Study. [PDF]

J Clin Med
Salvatore D, Campagna G, Padoan R, Pepe A, Amato A, Salvatore M.   +5 more
europepmc   +1 more source

Impact of Elexacaftor-Tezacaftor-Ivacaftor on Gastrointestinal Symptoms, Intestinal Ultrasound, and Pancreatic Stiffness in Cystic Fibrosis. [PDF]

Clin Transl Gastroenterol
Fraquelli M, Piagnani A, Corti F, Lanfranchi C, Casazza G, Colombo C.   +5 more
europepmc   +1 more source

Aging Gracefully: Does Elexacaftor/Tezacaftor/Ivacaftor Safety and Efficacy Stand the Test of Time? [PDF]

Am J Respir Crit Care Med
Wilson G, Hughes D.
europepmc   +1 more source

Elexacaftor-tezacaftor-ivacaftor and cystic fibrosis liver disease: A turning point that calls for cautious optimism. [PDF]

JHEP Rep
Rautou PE, Hillaire S, Gambazza S, Colombo C.   +3 more
europepmc   +1 more source

Impact of elexacaftor/tezacaftor/ivacaftor on gastrointestinal outcomes, inflammation, exocrine pancreatic function and fat malabsorption: Report of PROMISE pediatric substudy. [PDF]

J Cyst Fibros
Green N, Vu P, Xie J, Schwarzenberg SJ, Freedman S, Narkewicz M, Pittman J, Ratjen F, Rosenfeld M, Pope C, Duong J, Hoffman L, Heltshe S, Lusman SS, PROMISE Study Group.   +14 more
europepmc   +1 more source

Cystic fibrosis liver disease progression in the era of elexacaftor-tezacaftor-ivacaftor. [PDF]

JHEP Rep
Mouliade C, Parlati L, Tzedakis S, Collier M, Bouam S, Vallet-Pichard A, D'Halluin-Venier V, Kanaan R, Pol S, Sogni P, Burgel PR, Mallet V, Demosthenes Research Group.   +12 more
europepmc   +1 more source

The validated French CFAbd-Score reveals a lower burden of gastrointestinal symptoms in patients on Elexacaftor/Tezacaftor/Ivacaftor. [PDF]

J Pediatr Gastroenterol Nutr
Sermet-Gaudelus I, Sadrieh P, Bonnel AS, Enaud R, Wizla N, Languepin J, Nangui A, Deelawon A, Rave J, Dabelow S, Barucha A, Zagoya C, Duckstein F, Mainz JG.   +13 more
europepmc   +1 more source

The Changing Transplant Landscape in the Era of Elexacaftor/Tezacaftor/Ivacaftor: A Word of Caution. [PDF]

Clin Transplant
Semenchuk J, Tuff-Gordon E, Ma X, Sykes J, Cheng SY, Aversa M, Chaparro C, Tullis E, Stephenson AL.   +8 more
europepmc   +1 more source